ClinicalTrials.gg
Active, not recruitingNCT06333808ARTISTRY-2Updated Nov 5, 2026Results posted

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

A Phase 3 interventional study of Bictegravir/Lenacapavir (BIC/LEN) FDC and Lenacapavir in HIV-1-infection, sponsored by Gilead Sciences. Active, not recruiting at 104 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Updated Nov 5, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
577
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH) who are successfully treated with B/F/TAF (virologically suppressed).

The primary objective of this study is to evaluate the efficacy of switching to BIC/LEN (75/50 mg) FDC tablets versus continuing on B/F/TAF (50/200/25 mg) FDC tablets in virologically suppressed PWH.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Currently receiving B/F/TAF for at least 6 months prior to screening.
  • If plasma type 1 (HIV-1) ribonucleic acid (RNA) measurements in the last 6 months prior to screening are available, all levels must be \< 50 copies/mL.
  • At least one documented HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be \< 50 copies/mL.
  • Plasma HIV-1 RNA levels \< 50 copies/mL at screening.
  • No documented or suspected resistance to BIC (including integrase strand-transfer inhibitor resistant (INSTI-R) mutations T66A/I/K, E92G/Q, G118R, F121Y, Y143C/H/R, S147G, Q148H/K/R, N155H/S, or R263K in the integrase gene).
  • No documented or suspected resistance to tenofovir alafenamide (TAF) (TAF; mutations K65R, K65N, K70E, Q151M or T69 insertion, or ≥ 3 of the following thymidine analog mutations [M41L, D67N, K70R, L210W, T215Y/F, K219Q/E/N/R] in the reverse transcriptase gene).
  • Estimated ≥ 30 mL/min according to the formula for creatinine clearance.

Key Exclusion Criteria:

  • Positive serum pregnancy test or pregnant at screening or a positive pregnancy test prior to Day 1 randomization.
  • Breastfeeding (nursing).
  • Prior use of, or exposure to, LEN.
  • Active, serious infections (other than HIV-1) requiring parenteral therapy \< 30 days prior to randomization.
  • Active tuberculosis infection.
  • Acute hepatitis \< 30 days before randomization.
  • Chronic virus (HBV) infection, as determined by either:

    • Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit.
    • Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit.
  • Known to the study drug, its metabolites, or any formulation .
  • History of or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, or variceal bleeding).
  • Abnormal (ECG) at the screening visit that is as determined by the investigator.
  • Active requiring acute systemic therapy.
  • Any of the following laboratory values at screening:

    • > 5 × (ULN).
    • Direct > 1.5 × ULN.
    • \< 50,000/mm\^3.
    • \< 8.0 g/dL.
  • Requirement for ongoing therapy with or prior use of any prohibited medications listed in the protocol.
  • Participation or planned participation in any other clinical study (including observational studies) without prior approval from the sponsor.
  • Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
577 participants (actual)

Study arms

  • Experimental
    Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg

    Participants will switch from bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed-dose combination (FDC) tablets to bictegravir/lenacapavir (BIC/LEN) 75/50 mg FDC tablets + placebo-to-match (PTM) B/F/TAF tablets, administered orally, once daily up to 48 weeks. Participants will also receive a 2-day oral pharmacokinetic (PK) loading dose of LEN 600 mg on Days 1 and 2, in addition to the daily doses of BIC/LEN 75/50 mg and PTM B/F/TAF tablets starting on Day 1. At the end of blinded treatment (EBT) participants will enter the open label (OL) phase and continue to receive BIC/LEN 75 mg/50 mg FDC tablets through at least 48 weeks in the OL phase. At the OL Week 48, participants will be given an option to continue to receive BIC/LEN FDC tablets.

    Drug: Bictegravir/Lenacapavir (BIC/LEN) FDC · Drug: Lenacapavir · Drug: Placebo to match B/F/TAF

  • Active comparator
    Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg

    Participants will continue with their B/F/TAF 50/200/25 mg tablets and start PTM BIC/LEN tablets on Day 1 administered orally, once daily up to 48 weeks. Participants will receive PTM oral LEN PK loading tablets for 2 days (2 PTM LEN tablets on Day 1 and on Day 2). Participants who complete the EBT will be given an option to enter the OL phase to receive BIC/LEN FDC tablets.

    Drug: B/F/TAF · Drug: Placebo to match BIC/LEN FDC · Drug: Placebo to match Lenacapavir

  • Experimental
    Open-label Phase: BIC/LEN 75/50mg

    Participants from Treatment Group 1 will receive BIC/LEN FDC tablets through at least OL Week 48. At the OL Week 48 visit, participants from Treatment Group 1 will be given the option to continue to receive BIC/LEN FDC tablets. Participants in Treatment Group 2 who complete the EBT visit will be given the option to enter the OL phase to receive BIC/LEN FDC tablets. Participants from Treatment Group 2 who enter the OL phase will also receive a 2-day oral loading dose of LEN 600 mg (2 × 300 mg LEN on Day 1 and on Day 2). All participants who enter the OL phase may continue to receive BIC/LEN FDC tablets daily until study drug is available or until Gilead Sciences (Gilead) elects to discontinue the study.

    Drug: Bictegravir/Lenacapavir (BIC/LEN) FDC · Drug: Lenacapavir

Interventions

  • DrugBictegravir/Lenacapavir (BIC/LEN) FDC

    Drug pages: Bictegravir · Lenacapavir

    Tablets administered orally without regard to food

    Also known as: Bixlenvo™

  • Tablets administered orally without regard to food

    Also known as: GS-6207

  • DrugB/F/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    Tablets administered orally without regard to food

    Also known as: Biktarvy ®

  • DrugPlacebo to match B/F/TAF

    Tablets administered orally without regard to food

  • DrugPlacebo to match BIC/LEN FDC

    Tablets administered orally without regard to food

  • DrugPlacebo to match Lenacapavir

    Tablets administered orally without regard to food

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm

    Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and participants who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than adverse event (AE), death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window was between Days 295 and 378 (inclusively). Percentages were rounded off.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm

    Participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.

    Time frame: Week 48

  2. Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 48

    Time frame: Baseline, Week 48

  3. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 48

    An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC/LEN FDC, Treatment Group 1) or 30 days (for B/F/TAF, Treatment Group 2) or any AE leading to study drug discontinuation. Percentages were rounded off.

    Time frame: First dose date up to Week 48

  4. Treatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-Defined Snapshot Algorithm

    Time frame: Week 96

  5. Treatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by US FDA-Defined Snapshot Algorithm

    Time frame: Week 96

  6. Treatment Group 1: Change From Baseline in CD4 Cell Count at Week 96

    Time frame: Week 96

  7. Treatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 96

    Time frame: First dose date up to Week 96

  8. Treatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-Defined Snapshot Algorithm

    Time frame: Week 144

  9. Treatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by US FDA-Defined Snapshot Algorithm

    Time frame: Week 144

  10. Treatment Group 1: Change From Baseline in CD4 Cell Count at Week 144

    Time frame: Week 144

  11. Treatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 144

    Time frame: First dose date up to Week 144

07

Results

Posted Nov 5, 2026

Participant flow

Participants were enrolled at study sites in Asia, Europe, North America, Oceania and South America.

Participant flow — Overall Study
MilestoneBlinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg
Started384193
Completed00
Not completed384193
Withdrew: Still on study359173
Withdrew: Withdrew consent139
Withdrew: Adverse event53
Withdrew: Lost to follow-up53
Withdrew: Investigator's discretion12
Withdrew: Randomized but never treated12
Withdrew: Death01

Outcome measures

PrimaryPercentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm

Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and participants who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than adverse event (AE), death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window was between Days 295 and 378 (inclusively). Percentages were rounded off.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
percentage of participantsBlinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg
Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm1.31.0
Statistical analysis
  • Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg vs Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg · Difference in percentage: 0.3 · 95.002% CI -1.9 to 2.4Difference in percentages of participants between treatment groups (BIC/LEN versus B/F/TAF) and two-sided 95.002% confidence interval(CI) were based on Mantel-Haenszel stratum weights and Koch variance estimator and adjusted by geographic region.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm

Participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm
percentage of participantsBlinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm93.590.6
Statistical analysis
  • Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg vs Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg · Difference in percentage: 3.1 · 95.002% CI -1.8 to 8.0Difference in percentages of participants between treatment groups (BIC/LEN versus B/F/TAF) and two-sided 95.002% CI were constructed based on Mantel-Haenszel stratum weights and Koch variance estimator and adjusted by geographic region.
SecondaryChange From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · cells/µL
Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 48
cells/µLBlinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg
Baseline755 ± 301.4714 ± 271.8
Change at Week 48-20 ± 192.5-6 ± 164.0
Statistical analysis
  • Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg vs Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg · ANCOVA · p = 0.5964 · Difference in least squares mean: -8.4 · 95% CI -39.8 to 22.9P value, difference in least squares mean, and its 95% CI were from analysis of covariance ANCOVA model of change from baseline CD4 cell count with treatment as fixed effect and baseline CD4 cell count and geographic region as a covariates.
SecondaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC/LEN FDC, Treatment Group 1) or 30 days (for B/F/TAF, Treatment Group 2) or any AE leading to study drug discontinuation. Percentages were rounded off.

Time frame:
First dose date up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 48
percentage of participantsBlinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 4872.872.3
SecondaryTreatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-Defined Snapshot Algorithm
Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryTreatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by US FDA-Defined Snapshot Algorithm
Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryTreatment Group 1: Change From Baseline in CD4 Cell Count at Week 96
Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryTreatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 96
Time frame:
First dose date up to Week 96

Results for this outcome have not been posted.

SecondaryTreatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-Defined Snapshot Algorithm
Time frame:
Week 144

Results for this outcome have not been posted.

SecondaryTreatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by US FDA-Defined Snapshot Algorithm
Time frame:
Week 144

Results for this outcome have not been posted.

SecondaryTreatment Group 1: Change From Baseline in CD4 Cell Count at Week 144
Time frame:
Week 144

Results for this outcome have not been posted.

SecondaryTreatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 144
Time frame:
First dose date up to Week 144

Results for this outcome have not been posted.

Adverse events

Collected over All-Cause Mortality and Adverse Events: Up to 48 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg0/384 (0%)27/383 (7%)101/383 (26.4%)
Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg1/193 (0.5%)13/191 (6.8%)46/191 (24.1%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventBlinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg
Road traffic accidentInjury, poisoning and procedural complications0/3832/191
Coronary artery diseaseCardiac disorders0/3831/191
Abdominal painGastrointestinal disorders0/3831/191
Gait disturbanceGeneral disorders0/3831/191
CholecystitisHepatobiliary disorders0/3831/191
Escherichia bacteraemiaInfections and infestations0/3831/191
Gastroenteritis bacterialInfections and infestations0/3831/191
Postoperative abscessInfections and infestations0/3831/191
SepsisInfections and infestations0/3831/191
Staphylococcal infectionInfections and infestations0/3831/191
Most frequent other events
Most frequent other events
EventBlinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg
DiarrhoeaGastrointestinal disorders31/3839/191
NasopharyngitisInfections and infestations30/38313/191
Upper respiratory tract infectionInfections and infestations29/3839/191
NauseaGastrointestinal disorders20/38311/191
HeadacheNervous system disorders22/3836/191
Covid-19Infections and infestations5/38310/191

Baseline characteristics

The Safety Analysis Set included all participants who were randomized and took at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mgTotal
<=18 years000
Between 18 and 65 years339168507
>=65 years442367
Age, Continuous
Age, Continuous(Years)Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mgTotal
Mean48 ± 12.750 ± 11.949 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mgTotal
Female6942111
Male314149463
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mgTotal
Race — White199111310
Race — Black or African American11344157
Race — Asian512677
Race — Other or More Than One Race18927
Race — American Indian or Alaska Native112
Race — Native Hawaiian or Other Pacific Islander101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mgTotal
Ethnicity — Not Hispanic or Latino277141418
Ethnicity — Hispanic or Latino10649155
Ethnicity — Not Collected011
Region of Enrollment
Region of Enrollment(Participants)Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mgBlinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mgTotal
United States243114357
Taiwan311546
Canada171431
Germany21728
Japan15722
Australia11920
Italy12618
Spain4812
United Kingdom9211
Argentina549
Mexico628
Puerto Rico617
South Korea325
08

Study locations

104 sites

Showing the first 100 of 104 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Meissner EG, Ramgopal M, Ruane PJ, Sanchez W, Crofoot G, Routy JP, Brinson C, DeJesus E, Martorell CT, Tellez M, Yokomaku Y, O'Reilly M, Lupo S, Schellberg S, Lezama-Mora JI, Chin B, Aizen K, D'Antoni ML, Huang H, Mponponsuo K, Montezuma-Rusca JM, Sklar P, Rhee M, Hung CC; ARTISTRY-2 Study Group. Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet HIV. 2026 Aug;13(8):e538-e547. doi: 10.1016/S2352-3018(26)00078-0. Epub 2026 May 6. PubMed 42105781 ↗
  • Arora P, Hindman JT, West S, Ling J, Palaparthy R, Marathe DD. The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug-drug interaction study. Antimicrob Agents Chemother. 2026 Jan 7;70(1):e0078125. doi: 10.1128/aac.00781-25. Epub 2025 Nov 28. PubMed 41313173 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Oct 2025, 19 months.

Results were first posted in Nov 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2024
First posted
Mar 27, 2024
StartActual
Mar 25, 2024
Primary completionActual
Oct 27, 2025
CompletionEst.
Dec 2029
Results first posted
Nov 5, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 5, 2026
Interventions
Changed Bictegravir→Bictegravir/Lenacapavir (BIC/LEN) FDC. Added Drug: Placebo to match BIC/LEN FDC·Drug: Placebo to match Lenacapavir; removed Drug: Placebo to match BIC/LEN. Arm changed Treatment Group 2: B/F/TAF (50/200/25 mg) + PTM BIC/LEN→Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg. Arms added: Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg·Open-label Phase: BIC/LEN 75/50mg; arms removed: Treatment Group 1: Bictegravir (BIC)/ Lenacapavir (LEN) (75/50 mg) + PTM B/F/TAF
Nov 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProportionPercentage of Participants with With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 copiesCopies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA-defined) Defined Snapshot AlgorithmTime frame: Week 48
Nov 5, 2026
Documents
Secondary outcomes
6 edited, 1 time frame changed, 4 added
What changed in the outcomes
  • EditedProportionPercentage of Participants withWith HIV-1 RNA < 50 copiesCopies/mL at Week 48 as Determined by the US FDA-definedDefined Snapshot AlgorithmTime frame: Week 48
  • EditedTreatment Group 1: ProportionPercentage of Participants withWith HIV-1 RNA ≥ 50 copiesCopies/mL at Week 96 and Week 144 as Determined by the US FDA-definedDefined Snapshot AlgorithmTime frame: Week 96, Week 144 → Week 96
  • EditedTreatment Group 1: ProportionPercentage of Participants withWith HIV-1 RNA < 50 copiesCopies/mL at Week 96 and Week 144 as Determined by US FDA-definedDefined Snapshot AlgorithmTime frame: Week 96, Week 144 → Week 96
  • EditedTreatment Group 1: Change fromFrom Baseline in CD4 Cell Count at Week 96 and Week 144Time frame: Week 96, Week 144 → Week 96
  • EditedPercentage of Participants Experiencing Treatment-Emergent Adverse Events (AEsTEAEs) throughThrough Week 48Time frame: From first dose date up to Week 48 → First dose date up to Week 48
  • EditedTreatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs throughThrough Week 96 and Week 144Time frame: From first dose date up to Week 96 and Week 144 → First dose date up to Week 96
  • AddedTreatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-Defined Snapshot AlgorithmTime frame: Week 144
  • AddedTreatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by US FDA-Defined Snapshot AlgorithmTime frame: Week 144
  • AddedTreatment Group 1: Change From Baseline in CD4 Cell Count at Week 144Time frame: Week 144
  • AddedTreatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 144Time frame: First dose date up to Week 144
  • Time frameChange From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 48Baseline; Week 48 → Baseline, Week 48
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProportionPercentage of Participants with With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 copiesCopies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA-defined) Defined Snapshot AlgorithmTime frame: Week 48
    Secondary outcomes 6 edited, 1 time frame changed, 4 added
    What changed in the outcomes
    • EditedProportionPercentage of Participants withWith HIV-1 RNA < 50 copiesCopies/mL at Week 48 as Determined by the US FDA-definedDefined Snapshot AlgorithmTime frame: Week 48
    • EditedTreatment Group 1: ProportionPercentage of Participants withWith HIV-1 RNA ≥ 50 copiesCopies/mL at Week 96 and Week 144 as Determined by the US FDA-definedDefined Snapshot AlgorithmTime frame: Week 96, Week 144 → Week 96
    • EditedTreatment Group 1: ProportionPercentage of Participants withWith HIV-1 RNA < 50 copiesCopies/mL at Week 96 and Week 144 as Determined by US FDA-definedDefined Snapshot AlgorithmTime frame: Week 96, Week 144 → Week 96
    • EditedTreatment Group 1: Change fromFrom Baseline in CD4 Cell Count at Week 96 and Week 144Time frame: Week 96, Week 144 → Week 96
    • EditedPercentage of Participants Experiencing Treatment-Emergent Adverse Events (AEsTEAEs) throughThrough Week 48Time frame: From first dose date up to Week 48 → First dose date up to Week 48
    • EditedTreatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs throughThrough Week 96 and Week 144Time frame: From first dose date up to Week 96 and Week 144 → First dose date up to Week 96
    • AddedTreatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-Defined Snapshot AlgorithmTime frame: Week 144
    • AddedTreatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by US FDA-Defined Snapshot AlgorithmTime frame: Week 144
    • AddedTreatment Group 1: Change From Baseline in CD4 Cell Count at Week 144Time frame: Week 144
    • AddedTreatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 144Time frame: First dose date up to Week 144
    • Time frameChange From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 48Baseline; Week 48 → Baseline, Week 48
    Interventions Changed Bictegravir→Bictegravir/Lenacapavir (BIC/LEN) FDC. Added Drug: Placebo to match BIC/LEN FDC·Drug: Placebo to match Lenacapavir; removed Drug: Placebo to match BIC/LEN. Arm changed Treatment Group 2: B/F/TAF (50/200/25 mg) + PTM BIC/LEN→Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg. Arms added: Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg·Open-label Phase: BIC/LEN 75/50mg; arms removed: Treatment Group 1: Bictegravir (BIC)/ Lenacapavir (LEN) (75/50 mg) + PTM B/F/TAF
    + 5 other changes: identifiers, verification date, description, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06333808
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 27, 2024
Start date
Mar 25, 2024
Primary completion
Oct 27, 2025
Completion
Dec 2029 (estimated)
Results posted
Nov 5, 2026
Last update
Nov 5, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Lenacapavir

Start the discussion